These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 28447399)
21. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550 [TBL] [Abstract][Full Text] [Related]
22. Neuropsychological outcomes in adults commencing highly active anti-retroviral treatment in South Africa: a prospective study. Joska JA; Westgarth-Taylor J; Hoare J; Thomas KG; Paul R; Myer L; Stein DJ BMC Infect Dis; 2012 Feb; 12():39. PubMed ID: 22335937 [TBL] [Abstract][Full Text] [Related]
23. Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals. Kalayjian RC; Robertson KR; Albert JM; Fichtenbaum CJ; Brown TT; Taiwo BO; J Acquir Immune Defic Syndr; 2019 Jun; 81(2):e49-e54. PubMed ID: 30939531 [TBL] [Abstract][Full Text] [Related]
24. Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Blackstone K; Moore DJ; Franklin DR; Clifford DB; Collier AC; Marra CM; Gelman BB; McArthur JC; Morgello S; Simpson DM; Ellis RJ; Atkinson JH; Grant I; Heaton RK Clin Neuropsychol; 2012; 26(6):894-908. PubMed ID: 22708483 [TBL] [Abstract][Full Text] [Related]
25. A comparison of the sensitivity, stability, and reliability of three diagnostic schemes for HIV-associated neurocognitive disorders. Tierney SM; Sheppard DP; Kordovski VM; Faytell MP; Avci G; Woods SP J Neurovirol; 2017 Jun; 23(3):404-421. PubMed ID: 28108972 [TBL] [Abstract][Full Text] [Related]
26. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. Edén A; Marcotte TD; Heaton RK; Nilsson S; Zetterberg H; Fuchs D; Franklin D; Price RW; Grant I; Letendre SL; Gisslén M PLoS One; 2016; 11(6):e0157160. PubMed ID: 27295036 [TBL] [Abstract][Full Text] [Related]
27. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. Burdo TH; Weiffenbach A; Woods SP; Letendre S; Ellis RJ; Williams KC AIDS; 2013 Jun; 27(9):1387-95. PubMed ID: 23435298 [TBL] [Abstract][Full Text] [Related]
28. Cannabis Exposure is Associated With a Lower Likelihood of Neurocognitive Impairment in People Living With HIV. Watson CW; Paolillo EW; Morgan EE; Umlauf A; Sundermann EE; Ellis RJ; Letendre S; Marcotte TD; Heaton RK; Grant I J Acquir Immune Defic Syndr; 2020 Jan; 83(1):56-64. PubMed ID: 31809361 [TBL] [Abstract][Full Text] [Related]
39. Prevalence and 1-year incidence of HIV-associated neurocognitive disorder (HAND) in adults aged ≥50 years attending standard HIV clinical care in Kilimanjaro, Tanzania. Flatt A; Gentry T; Kellett-Wright J; Eaton P; Joseph M; Urasa S; Howlett W; Dekker M; Kisoli A; Rogathe J; Henderson L; Lewis T; Thornton J; McCartney J; Yarwood V; Irwin C; Mukaetova-Ladinska EB; Akinyemi R; Gray WK; Walker RW; Dotchin CL; Quaker AS; Makupa PC; Paddick SM Int Psychogeriatr; 2023 Jul; 35(7):339-350. PubMed ID: 33757616 [TBL] [Abstract][Full Text] [Related]
40. Is the use of the QPC cognitive complaints questionnaire relevant for the screening strategy of HIV-Associated neurocognitive disorders? Zaegel-Faucher O; Laroche H; Tixier M; Morisseau V; Obry-Roguet V; Poizot-Martin I AIDS Care; 2021 Mar; 33(3):389-397. PubMed ID: 32279542 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]